198 related articles for article (PubMed ID: 24836358)
1. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T
PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
[TBL] [Abstract][Full Text] [Related]
3. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
[TBL] [Abstract][Full Text] [Related]
6. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
[TBL] [Abstract][Full Text] [Related]
7. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
8. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM
Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status.
Reynolds A; Doggett EA; Riddle SM; Lebakken CS; Nichols RJ
Front Mol Neurosci; 2014; 7():54. PubMed ID: 25009464
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
[TBL] [Abstract][Full Text] [Related]
13. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3 proteins are promising LRRK2 interactors.
Rudenko IN; Cookson MR
Biochem J; 2010 Sep; 430(3):e5-6. PubMed ID: 20795948
[TBL] [Abstract][Full Text] [Related]
15. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.
Purlyte E; Dhekne HS; Sarhan AR; Gomez R; Lis P; Wightman M; Martinez TN; Tonelli F; Pfeffer SR; Alessi DR
EMBO J; 2018 Jan; 37(1):1-18. PubMed ID: 29212815
[TBL] [Abstract][Full Text] [Related]
16. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
[TBL] [Abstract][Full Text] [Related]
17. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
[TBL] [Abstract][Full Text] [Related]
18. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 dephosphorylation increases its ubiquitination.
Zhao J; Molitor TP; Langston JW; Nichols RJ
Biochem J; 2015 Jul; 469(1):107-20. PubMed ID: 25939886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
